Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DTA-H19 · 1 trial · 1 indication
If 2 patients in any cohort experience DLTs, then the next lower dose will be considered the MTD if there is a lower dose cohort. A DLT is defined as grade 3 or greater toxicity judged to be at least possibly related to the investigational products.
| Arm | Type | Description |
|---|---|---|
| BC-819 | EXPERIMENTAL | Intratumoral administration of BC-819 |
| Name | Type | Description |
|---|---|---|
| DTA-H19 | BIOLOGICAL | Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks |
Inclusion Criteria: * Provide written informed consent and be between the ages of 18 and 79, inclusive. * Have unresectable, locally advanced adenocarcinoma of the pancreas proven by biopsy or cytology (defined as direct extension to the superior mesenteric artery and/or celiac axis with loss of a ...
DTA-H19 is an investigational monoclonal antibody being studied for the treatment of pancreatic neoplasms, specifically unresectable pancreatic cancer. It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
DTA-H19 is being developed by Chemomab Therapeutics Ltd., a biopharmaceutical company traded on the Nasdaq under the ticker symbol CMMB.
DTA-H19 is in Phase 1 clinical development. A Phase 1/2a study of DTA-H19 in patients with unresectable pancreatic cancer has been completed.
DTA-H19 has been studied in a Phase 1/2a clinical trial registered as NCT00711997, which evaluated the drug in patients with unresectable pancreatic cancer. This trial was conducted in the United States and Israel and has been completed.
Yes, DTA-H19 is a monoclonal antibody, a type of biologic drug designed to target specific proteins involved in disease processes.